SeqOne Genomics Secures €20 Million to Drive AI-Powered NGS Revolution
Deal News | May 22, 2025 | Omnes Capital SAS
SeqOne Genomics, an innovator in AI-driven genomic diagnostics for personalized medicine, has successfully raised €20 million in an oversubscribed growth funding round. The round was led by Supernova Invest with ongoing support from existing investors Elaia, Omnes Capital, and Merieux Equity Partners. This substantial investment aims to bolster SeqOne's international expansion, especially in the U.S., and strengthen its strategic growth agenda. The funding will propel SeqOne's mission to be a leader in the Next-Generation Sequencing (NGS) field, focusing on precise and scalable genomic data analysis. Through this capital, SeqOne is positioned to expand its operations across three main pillars: international scaling, U.S. market penetration with a compliance-oriented platform, and strategic acquisitions. Notably, the company has recently acquired Life & Soft to enhance its multi-omics capabilities.
Sectors
- Biotechnology
- Medical Technology
- Private Equity
Geography
- France – SeqOne Genomics is a France-based company and majority of its key investors, including Omnes Capital, are also located in France.
- United States – SeqOne Genomics plans to expand operations significantly in the U.S. market with its HIPAA-compliant platform.
Industry
- Biotechnology – The industry focuses on the use of living organisms or systems to develop products, in this case, leveraging AI for genomic diagnostics.
- Medical Technology – The sector involves the application of technology to improve healthcare, such as AI-powered NGS for personalized medicine.
- Private Equity – Involves investment firms like Omnes Capital providing financial support for growth and expansion, as demonstrated in the article.
Financials
- €20 million – The total investment amount raised by SeqOne in the oversubscribed growth funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| SeqOne Genomics | Target Company | Company | A leading AI-driven genomic diagnostics company aiming to revolutionize personalized medicine. |
| Supernova Invest | Lead Investor | Company | The leading new investor in SeqOne's funding round. |
| Elaia Partners | Investor | Company | An existing investor providing continued support in the current funding round. |
| Omnes Capital SAS | Investor | Company | A private equity firm and consistent investor in SeqOne Genomics. |
| Merieux Equity Partners | Investor | Company | An investor providing ongoing support in the current funding round. |
| Life & Soft | Recent Acquisition | Company | A company recently acquired by SeqOne for its multi-omics expertise. |